Research Device – Talk Bio

Strategic solutions for cost, time and quality challenges in drug development – recent developments

3 days ago talkbio0Tagged Acceleration, Candidiasis, Chronic Mucocutaneous, CDMO/CRO, Clinical Development, cost-reduction, Drug Development, Efficiency, Optimization, Pharma, quality management, Study models, supply chain risk, TimeLine Fluoride Releasing Resin

drug development; cost reduction; timeline acceleration; quality management; integrated CDMO/CRO models; AI in pharma; CMC optimization; clinical development efficiency; supply chain risk; biotech strategy

Recent Advances in AI & Multi-Omics for Translational Research

2 weeks ago talkbio0Tagged agentic AI, AI-driven, Biological Markers, Cancer Research, Discover, DNA Integration, drug response, Machine Learning, Multiomics, Precision Medicine, Prediction, Stratification, Study models, Translational Research, Biomedical

AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction

Terray Therapeutics Unveils EMMI: AI-Driven Platform Revolutionizes Small Molecule Drug Discovery

3 weeks ago talkbio0Tagged AI-native platform, chemical space, drug optimization, EMMI, Generative AI, Machine Learning, Nasua, small molecule drug discovery, Study models, Terray Therapeutics

Terray Therapeutics; EMMI; generative AI; small molecule drug discovery; AI-native platform; chemical space; drug optimization; biotech; machine learning; COATI model

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

2 months ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

2 months ago talkbio0Tagged Advanced therapies, Alternative, Cells, Clinical Trials, commercialization, Gene Modification, gene therapy, Industry, meeting, MESA, partnerships, payment, Phoenix Arizona, regulatory challenges, RNA, Messenger, Study models

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3

9 months ago talkbio0Tagged molecular glues, Neo-1, Study models

Neo-1, Study models, molecular glues

Hospital Group Seeks to Intervene in Lawsuit Against Lilly’s 340B Rebate Model

10 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, hospital intervention, Study models, United States Health Resources and Services Administration

340B Drug Pricing Program, Eli Lilly, rebate model, lawsuit, hospital intervention, Health Resources and Services Administration (HRSA), drug pricing

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

11 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models

Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology

11 months ago talkbio0Tagged Alanine Transaminase, Artificial Intelligence, biology (field), Bioptimus, Cathay Innovation, Drug Industry, medical innovation, Study models

Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

1 year ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation